Main Article Content
Background: The study aimed to optimize and validate a nano-particulate technology for the sustained release
of perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor, using a box-behnken experimental
methodology. Methods: The researcher used a Box-behnken experimental methodology to optimize the
formulation and assess various characteristics such as particle size, zeta potential, surface shape, encapsulation
efficiency and in vitro drug release. The nanoparticles characterization findings were recorded included the size,
polydispersity index, zeta potential and encapsulation efficiency. Results: The nanoparticles had a smooth surface
and their size was determined to be 122.38 ± 0.75 nm. The polydispersity index was 0.298, the zeta potential
was 38.79 ± 0.05 mv and the encapsulation efficiency was 61.73 ± 0.06%. In vitro release was restricted for up
to two hours, but at a pH of 7.4, the rate of drug release increased and was maintained. Conclusion: The study
concluded that the nano-particulate technology for the potential to improve therapeutic efficacy and decrease
dosage frequency for drug that need repeated doses such as perindopril erbumine.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.